EGFR and non-small cell lung carcinoma: <b>Conclusion:</b> Addition of bevacizumab to EGFR-TKI therapy provided significantly better PFS and ORR for EGFR-mutant advanced NSCLC patients, though with higher risk of grade≥3 TRAEs.